PharmaCorp Rx Inc.
PCRX.V
TSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 5.27% | -6.29% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.27% | -6.29% | |||
| Cost of Revenue | 2.73% | -6.68% | |||
| Gross Profit | 9.27% | -5.65% | |||
| SG&A Expenses | 14.06% | -23.42% | |||
| Depreciation & Amortization | -7.26% | 3.34% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.14% | -12.83% | |||
| Operating Income | -128.18% | 91.92% | |||
| Income Before Tax | -26.88% | 121.91% | |||
| Income Tax Expenses | -278.69% | -102.51% | |||
| Earnings from Continuing Operations | -6.57% | 114.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -374.07% | 37.79% | |||
| Net Income | -72.62% | 111.90% | |||
| EBIT | -128.18% | 91.92% | |||
| EBITDA | -32.72% | 175.35% | |||
| EPS Basic | -75.00% | 109.09% | |||
| Normalized Basic EPS | -150.00% | 111.11% | |||
| EPS Diluted | -75.00% | 109.09% | |||
| Normalized Diluted EPS | -150.00% | 111.11% | |||
| Average Basic Shares Outstanding | 0.00% | 17.09% | |||
| Average Diluted Shares Outstanding | -0.07% | 23.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||